ArticleFrontiers in cardiovascular medicine2025
Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early Post-STEMI Cardiac Rehabilitation in the CSC-Infarct Program: Real-World Safety and Effectiveness of Individualized Training Protocols.Journal of clinical medicine · 2026Article
- Establishment and validation of an interpretable machine learning-based predictive model for risk of post-PCI in-hospital heart failure in AIHD patients.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute ST-elevation myocardial infarction (STEMI) is a frequent and serious presentation of acute coronary syndrome. The STOP-SCA+ study aimed to (i) describe 1-year compliance to secondary prevention cardiac tri-therapy and (ii) identify factors associated with negative outcomes 1 year after STEMI, particularly the impact of compliance and rehabilitation care. Methods: Patients who were >18 years old and hospitalized for STEMI in five interventional cardiac centers with the same cardiac registry in one French region (2.5 million inhabitants), between 2014 and 2018, were included. After a probabilistic matching with the National Health Insurance database [Système National des Données de Santé (SNDS), 96% matching], compliance for cardiac tri-therapy was studied: aspirin, P2Y12 inhibitor, and statin. Factors associated with poor outcomes (ischemic complications, death) were analyzed using Cox modeling and those for compliance by logistic regression. Results: A total of 3,768 patients were included, of whom 84% underwent primary percutaneous coronary intervention. At 1 year, 3,362 had at least one tri-therapy delivery (89.2%), of whom 53% were compliant, and 2,478 patients went to cardiac rehabilitation (65.8%). Death occurred in 130 patients and/or ischemic complications in 194 (total of poor outcomes 8.0%). Compliance was not associated with complications over the year [HR 1.16 (0.86-1.57)], while the absence of cardiac rehabilitation [2.31 (1.73-3.08)] was associated, as well as female sex 1.54 (1.08-2.19), renal impairment [2.87 (1.49-5.53)], initial STEMI clinical presentation [pejorative Killip 2.04 (1.19-3.50)], and LVEF <40% at discharge [2.22 (1.65-2.99)]. Additionally, cardiac rehabilitation was associated with compliance [OR 1.55 (1.34-1.79)]. Discussion: Pejorative outcomes 1 year after a STEMI represented 8% of cases, mainly related to patient features, the initial clinical presentation, and the absence of access to rehabilitation. Compliance part in patient health outcomes will need further modeling to accurately study its impact. Matching clinical and medico-administrative databases proved to be relevant for assessing outcomes at a large scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.